Argitalpenak (14) Ikertzaileren baten partaidetza izan duten argitalpenak

2023

  1. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

    Leukemia and Lymphoma

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Blood cancer journal

  5. Disease Monitoring In Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia

  6. Highs and lows of t(4;14) in multiple myeloma

    Blood

  7. Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients with Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

    HemaSphere

  8. Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

    HemaSphere

  9. RROL lncRNA role in multiple myeloma

    Blood

  10. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

  11. Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma

    The Lancet Haematology

  12. The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis

    OncoImmunology

  13. The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research

  14. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology